Table 1 The characteristics of the patient population
From: Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer
Clinical parameters | Training set | Test set | ||||
|---|---|---|---|---|---|---|
CPT1A level | CPT1A level | |||||
High | Low | p Value | High | Low | p Value | |
Age | ||||||
  ≤ 60 | 85 (28.2) | 95 (31.6) | 0.269 | 43 (33.3) | 48 (37.2) | 0.407 |
  > 60 | 65 (21.6) | 56 (18.6) |  | 21 (16.3) | 17 (13.2) | |
Menopausal status, n (%) | ||||||
 Premenopausal | 76 (25.2) | 85 (28.2) | 0.328 | 35 (27.1) | 40 (31.0) | 0.430 |
 postmenopausal | 74 (24.6) | 66 (21.9) |  | 29 (22.5) | 25 (19.4) |  |
Tumor size, n (%) | ||||||
 Tis | 5 (3.9) | 20 (15.5) | 0.000 | 4 (3.1) | 8 (7.0) | 0.033 |
 T1 | 44 (34.1) | 52 (40.3) |  | 16 (12.4) | 30 (23.3) |  |
 T2 | 84 (65.1) | 76 (58.9) |  | 35 (27.1) | 24 (18.6) |  |
 T3 | 13 (10.1) | 3 (2.3) |  | 7 (5.4) | 3 (2.3) |  |
 T4 | 4 (3.1) | 0 (0.0) |  | 2 (1.6) | 0 (0.0) |  |
Lymph node status, n (%) | ||||||
 N0 | 75 (24.9) | 108 (35.9) | 0.001 | 33 (25.6) | 49 (38.0) | 0.004 |
 N1 | 39 (13.0) | 24 (8.0) |  | 12 (9.3) | 11 (8.5) |  |
 N2 | 17 (5.6) | 13 (4.3) |  | 7 (5.4) | 4 (3.1) |  |
 N3 | 19 (6.3) | 6 (2.0) |  | 12 (9.3) | 1 (0.8) |  |
TNM stage, n (%) | ||||||
 0 | 5 (1.7) | 20 (6.6) | 0.000 | 4 (3.1) | 8 (6.2) | 0.000 |
 I | 27 (9.0) | 41 (13.6) |  | 6 (4.7) | 25 (19.4) |  |
 IIA | 48 (15.9) | 53 (17.6) |  | 24 (18.6) | 15 (11.6) |  |
 IIB | 25 (8.3) | 19 (6.3) |  | 7 (5.4) | 10 (7.8) |  |
 III | 39 (13.0) | 15 (5.0) |  | 19 (14.7) | 6 (4.7) |  |
 IV | 6 (2.0) | 3 (1.0) |  | 4 (3.1) | 1 (0.8) |  |
Histological grading, n (%) | ||||||
 G1 | 9 (3.0) | 22 (7.3) | 0.045 | 2 (1.6) | 15 (11.6) | 0.000 |
 G2 | 82 (27.2) | 81 (26.9) |  | 25 (19.4) | 33 (25.6) |  |
 G3 | 56 (18.6) | 47 (15.6) |  | 35 (27.1) | 16 (12.4) |  |
 Unkown | 3 (1.0) | 1 (0.3) |  | 2 (1.6) | 1 (0.8) |  |
ER, n (%) | ||||||
 Negative | 64 (21.3) | 61 (20.3) | 0.690 | 13 (10.1) | 22 (17.1) | 0.063 |
 Positive | 86 (28.6) | 90 (29.9) |  | 51 (39.5) | 42 (33.3) |  |
PR, n (%) | ||||||
  ≤ 20 | 71 (23.6) | 79 (26.2) | 0.387 | 28 (21.7) | 21 (16.3) | 0.181 |
  > 20 | 79 (26.2) | 72 (23.9) |  | 36 (27.9) | 44 (34.1) |  |
HER2, n (%) | ||||||
 Negative | 108 (35.9) | 85 (28.2) | 0.004 | 47 (36.4) | 36 (27.9) | 0.032 |
 Positive | 42 (14.0) | 66 (21.9) |  | 17 (13.2) | 29 (22.5) |  |
Ki67, n (%) | ||||||
  < 15% | 20 (6.6) | 33 (11.0) | 0.052 | 14 (10.9) | 20 (15.5) | 0.252 |
  ≥ 15% | 130 (43.2) | 118 (39.2) |  | 50 (38.8) | 45 (34.9) |  |
Molecular subtype, n (%) | ||||||
 Luminal A | 11 (3.7) | 18 (6.0) | 0.000 | 7 (5.4) | 15 (11.6) | 0.033 |
 Luminal B/HER2- | 59 (19.6) | 52 (17.3) |  | 23 (17.8) | 33 (25.6) |  |
 Luminal B/HER2+ | 16 (5.3) | 21 (7.0) |  | 12 (9.3) | 9 (7.0) |  |
 HER2+ | 23 (7.6) | 44 (14.6) |  | 9 (7.0) | 4 (3.1) |  |
 TNBC | 41 (13.6) | 16 (5.3) |  | 13 (10.1) | 4 (3.1) |  |